{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:08:38Z","timestamp":1781222918356,"version":"3.54.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dadr.2026.100440","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:59:14Z","timestamp":1777046354000},"page":"100440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A rapid review of the effects of GLP-1 receptor agonists on opioid and stimulant use-related outcomes"],"prefix":"10.1016","volume":"19","author":[{"given":"Marisa","family":"Leach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8845-663X","authenticated-orcid":false,"given":"Megan E.","family":"Marziali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surita","family":"Parashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Bondy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Guillemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine W.","family":"Kooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio S.G.","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dadr.2026.100440_bib1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s12884-024-06879-0","article-title":"Socioecological factors influencing the risk of developing hypertensive disorders of pregnancy in India: a rapid review","volume":"24","author":"Alur","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.dadr.2026.100440_bib2","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2024","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2026.100440_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2025.07.001","article-title":"Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens","volume":"98","author":"Aran\u00e4s","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.dadr.2026.100440_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/brainsci14060617","article-title":"Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach","volume":"14","author":"Arillotta","year":"2024","journal-title":"Brain Sci."},{"issue":"3","key":"10.1016\/j.dadr.2026.100440_bib5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.dadr.2026.100440_bib6","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eNeuro"},{"key":"10.1016\/j.dadr.2026.100440_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drugalcdep.2014.02.702","article-title":"Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors","volume":"139","author":"Brecht","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2026.100440_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.physbeh.2019.03.029","article-title":"The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review","volume":"206","author":"Brunchmann","year":"2019","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.dadr.2026.100440_bib9","unstructured":"Canada\u2019s Drug Agency-L\u2019Agence de m\u00e9dicaments du Canada. (2022, September 1). Utilization of Glucagon-Like Peptide-1 Receptor Agonists. CDA-AMC. \u3008https:\/\/www.cda-amc.ca\/utilization-glucagon-peptide-1-receptor-agonists\u3009"},{"key":"10.1016\/j.dadr.2026.100440_bib10","unstructured":"Centers for Disease Control and Prevention. 2026Nonfatal Drug Overdose Surveillance and Epidemiology Syndromic Surveillance (DOSE-SYS) System [Dataset]. Atlanta, GA: US Department of Health and Human Services, CDC. \u3008https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/dose-dashboard-nonfatal-surveillance-data.html\u3009"},{"issue":"12","key":"10.1016\/j.dadr.2026.100440_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.dadr.2026.100440_bib12","first-page":"1","article-title":"GLP-1 receptor agonists and substance use disorders in older adults with type 2 diabetes: a target trial emulation","author":"Dai","year":"2025","journal-title":"Obesity"},{"issue":"5","key":"10.1016\/j.dadr.2026.100440_bib13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","article-title":"Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress- and drug-induced heroin seeking in rats","volume":"33","author":"Douton","year":"2022","journal-title":"Behav. Pharmacol."},{"issue":"4","key":"10.1016\/j.dadr.2026.100440_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin seeking behavior in rats","volume":"32","author":"Douton","year":"2021","journal-title":"Behav. Pharmacol."},{"issue":"2","key":"10.1016\/j.dadr.2026.100440_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats","volume":"27","author":"Douton","year":"2021","journal-title":"Addict. Biol."},{"issue":"25","key":"10.1016\/j.dadr.2026.100440_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: population estimates \u2014 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"Mmwr. Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.dadr.2026.100440_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res. Bull."},{"issue":"5","key":"10.1016\/j.dadr.2026.100440_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112466","article-title":"GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity","volume":"42","author":"Falk","year":"2023","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.dadr.2026.100440_bib19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jsat.2007.12.008","article-title":"The economic costs of substance abuse treatment: updated estimates and cost bands for program assessment and reimbursement","volume":"35","author":"French","year":"2008","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2026.100440_bib20","first-page":"1","article-title":"Exendin-4","author":"Furman","year":"2007","journal-title":"xPharm Compr. Pharmacol. Ref."},{"issue":"6","key":"10.1016\/j.dadr.2026.100440_bib21","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/dom.14663","article-title":"Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms","volume":"24","author":"Ghidewon","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.dadr.2026.100440_bib22","unstructured":"Health Canada, Public Health Agency of Canada, & U.S. Department of Health and Human Services. 2022Canada-U.S. joint white paper: Substance use and harms during the COVID-19 pandemic and approaches to federal surveillance and response. U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health. \u3008https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canada-us-white-paper-substance-use-harms-during-covid-19-pandemic-approaches-federal-surveillance-response.html\u3009"},{"issue":"4","key":"10.1016\/j.dadr.2026.100440_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.dadr.2026.100440_bib24","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"5\u20136","key":"10.1016\/j.dadr.2026.100440_bib25","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","article-title":"The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide","volume":"62","author":"Kanoski","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.dadr.2026.100440_bib26","article-title":"W162 - Strategies to improve equitable and evidence-based hospital care for pregnant people with a substance use disorder: a rapid scoping review","volume":"267","author":"King","year":"2025","journal-title":"Drug Alcohol Depend. Abstr. 2024 Annu. Meet. Coll. Probl. Drug Depend."},{"issue":"1","key":"10.1016\/j.dadr.2026.100440_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13643-022-02011-5","article-title":"Paper 2: performing rapid reviews","volume":"11","author":"King","year":"2022","journal-title":"Syst. Rev."},{"key":"10.1016\/j.dadr.2026.100440_bib28","doi-asserted-by":"crossref","unstructured":"Leach, M., Marziali, M., Parashar, S., Montaner, J., Bondy, G., Guillemi, S., Harris, M., Hull, M., Stone, S., Kooji, K., & Hogg, R.S. (2025). A rapid review on the effects of GLP-1 receptor agonists on opioid and stimulant use-related outcomes. OSF Registries. \u3008https:\/\/doi.org\/10.17605\/OSF.IO\/AZ9JK\u3009","DOI":"10.1016\/j.dadr.2026.100440"},{"key":"10.1016\/j.dadr.2026.100440_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.dadr.2026.100440_bib30","unstructured":"Li, T., Higgins, J., & Deeks, J. (2019). Chapter 5: Collecting data. In Cochrane Handbook for Systematic Reviews of Interventions. \u3008https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-05#section-5-3\u3009"},{"key":"10.1016\/j.dadr.2026.100440_bib31","article-title":"Therapeutic potential of the novel GLP-1 receptor agonist semaglutide in alcohol use disorder","author":"Liu","year":"2025","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.dadr.2026.100440_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2017.04.016","article-title":"Relapse to opioid use disorder after inpatient treatment: protective effect of injection naltrexone","volume":"85","author":"Nunes","year":"2018","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2026.100440_bib33","unstructured":"Office of the Commissioner. (2024, December 23). FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes. FDA. FDA. \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes\u3009"},{"key":"10.1016\/j.dadr.2026.100440_bib34","unstructured":"Opioid use disorder and treatment. (2023, July 25). [Education and awareness]. \u3008https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/opioids-use-disorder-treatment.html\u3009"},{"issue":"8","key":"10.1016\/j.dadr.2026.100440_bib35","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/add.14947","article-title":"The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada","volume":"115","author":"Piske","year":"2020","journal-title":"Addiction"},{"issue":"12","key":"10.1016\/j.dadr.2026.100440_bib36","doi-asserted-by":"crossref","first-page":"E387","DOI":"10.5489\/cuaj.8678","article-title":"Impact of antibiotic prophylaxis on urinary tract infection recurrence in children","volume":"18","author":"Potvin","year":"2024","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.dadr.2026.100440_bib37","unstructured":"Provincial Health Services Authority. (n.d.). Call Volumes in B.C. Communities. BC Emergency Health Services. Retrieved February 2, 2026, from \u3008https:\/\/www.bcehs.ca:443\/about\/accountability\/data\/call-volumes\u3009"},{"issue":"2","key":"10.1016\/j.dadr.2026.100440_bib38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2026.100440_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.dadr.2026.100440_bib40","unstructured":"Response to the Opioid Overdose Crisis in Vancouver Coastal Health. (2018). [Chief Medical Health Officer Report]. Vancouver Coastal Health. \u3008https:\/\/www.vch.ca\/sites\/default\/files\/import\/documents\/CMHO-report.pdf\u3009"},{"issue":"7","key":"10.1016\/j.dadr.2026.100440_bib41","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/npp.2015.362","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area decreases the reinforcing efficacy of cocaine","volume":"41","author":"Schmidt","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"9662","key":"10.1016\/j.dadr.2026.100440_bib42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0140-6736(09)60009-X","article-title":"Alcohol-use disorders","volume":"373","author":"Schuckit","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.dadr.2026.100440_bib43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol. & Behav."},{"key":"10.1016\/j.dadr.2026.100440_bib44","unstructured":"Stimulant Use Disorder Practice Update. (2022). British Columbia Centre on Substance Use. \u3008https:\/\/www.bccsu.ca\/wp-content\/uploads\/2022\/06\/Stimulant-Use-Disorder-Practice-Update_June2022.pdf\u3009"},{"key":"10.1016\/j.dadr.2026.100440_bib45","unstructured":"Substance Abuse and Mental Health Services Administration. (2025). Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health ((HHS Publication No. PEP25-07-007, NSDUH Series H-60)). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt56287\/2024-nsduh-annual-national-report.pdf."},{"key":"10.1016\/j.dadr.2026.100440_bib46","unstructured":"Substance-related Overdose and Mortality Surveillance Task Group on behalf of the Council of Chief Medical Officers of Health. (2025). Opioid- and Stimulant-related Harms in Canada [Datasets;statistics;education and awareness]. Ottawa: Public Health Agency of Canada. \u3008https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/maps.html\u3009"},{"key":"10.1016\/j.dadr.2026.100440_bib47","doi-asserted-by":"crossref","unstructured":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. (2020). Journal of Addiction Medicine, 14(2S), 1\u201391. \u3008https:\/\/doi.org\/10.1097\/ADM.0000000000000633\u3009","DOI":"10.1097\/ADM.0000000000000633"},{"key":"10.1016\/j.dadr.2026.100440_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","article-title":"The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice","volume":"160","author":"Thomsen","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.dadr.2026.100440_bib49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12916-015-0465-6","article-title":"A scoping review of rapid review methods","volume":"13","author":"Tricco","year":"2015","journal-title":"BMC Med."},{"issue":"7","key":"10.1016\/j.dadr.2026.100440_bib50","doi-asserted-by":"crossref","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.dadr.2026.100440_bib51","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat. Neurosci."},{"issue":"8","key":"10.1016\/j.dadr.2026.100440_bib52","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.37765\/ajmc.2025.89778","article-title":"Trends in glucagon-like peptide 1 receptor agonist prescribing patterns","volume":"31","author":"Ukhanova","year":"2025","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.dadr.2026.100440_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","article-title":"Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats","volume":"189","author":"Urbanik","year":"2022","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.dadr.2026.100440_bib54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/FBP.0000000000000805","article-title":"Effect of acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, and estrus phase on cue- and drug-induced fentanyl seeking in female rats","volume":"36","author":"Urbanik","year":"2024","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.dadr.2026.100440_bib55","unstructured":"Veritas Health Innovation. (n.d.). Covidence systematic review software [Computer software]. Retrieved January 30, 2026, from \u3008https:\/\/www.covidence.org\/\u3009"},{"issue":"9","key":"10.1016\/j.dadr.2026.100440_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2026.100440_bib57","unstructured":"What is PICO? (n.d.). Cochrane Library. Retrieved January 5, 2026, from \u3008https:\/\/www.cochranelibrary.com\/about-pico\u3009"},{"issue":"5","key":"10.1016\/j.dadr.2026.100440_bib58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic & Clin. Pharmacol. & Toxicol."},{"issue":"10","key":"10.1016\/j.dadr.2026.100440_bib59","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob. Res."},{"issue":"3","key":"10.1016\/j.dadr.2026.100440_bib60","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats","volume":"45","author":"Zhang","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.dadr.2026.100440_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats","volume":"192","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.dadr.2026.100440_bib62","article-title":"Glucagon-like peptide-1 analog exendin-4 ameliorates cocaine-mediated behavior by inhibiting toll-like receptor 4 signaling in mice","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724626000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724626000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:45:34Z","timestamp":1781221534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724626000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":62,"alternative-id":["S2772724626000338"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2026.100440","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rapid review of the effects of GLP-1 receptor agonists on opioid and stimulant use-related outcomes","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2026.100440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100440"}}